Risk Assessment of Cancer-Associated Thrombotic Events

Abstract

Cancer-associated thrombotic events, particularly venous thromboembolism (VTE), represent a significant contributor to morbidity and mortality among oncology patients. The multifaceted interplay between malignancy, patient-specific factors, and therapeutic interventions necessitates a nuanced approach to risk assessment, early detection, and prevention of thrombotic complications. This review synthesizes current epidemiological data, elucidates the mechanistic underpinnings of cancer-associated thrombosis, and summarizes established and emerging strategies for risk stratification and management, with a focus on clinical relevance and evidence-based recommendations for healthcare professionals.

Introduction

Thrombotic events are among the most common and serious complications in patients with malignancy. The hypercoagulable state induced by cancer, coupled with other risk factors such as chemotherapy and immobilization, leads to a substantially increased risk of events like deep vein thrombosis (DVT) and pulmonary embolism (PE). These thrombotic complications not only affect prognosis but also impact therapeutic decision-making, quality of life, and healthcare resource utilization. A comprehensive understanding of the risk factors, pathophysiology, and management options is imperative for optimizing outcomes in this vulnerable patient population.

Epidemiology / Disease Burden

Cancer patients face a four- to seven-fold increased risk of venous thromboembolism compared to the general population, and VTE is the second leading cause of death in this group after disease progression. The incidence varies widely by cancer type, stage, and therapeutic regimens, with pancreatic, gastric, brain, lung, and hematological malignancies carrying the highest risk. Recent population-based studies estimate that up to 20% of all VTE cases are cancer-associated. Notably, the risk is highest in the initial months following a cancer diagnosis and during periods of active therapy. Mortality rates are substantially elevated when thrombotic events occur, and recurrent VTE is more frequent among cancer patients despite anticoagulation.

Pathophysiology

The pathogenesis of cancer-associated thrombosis is complex, involving multiple pathways that fulfill Virchow\"s triad: hypercoagulability, stasis, and endothelial injury. Tumor cells directly activate coagulation via expression of tissue factor and cancer procoagulant. They also release pro-inflammatory cytokines and microparticles, which further stimulate thrombin generation and platelet activation. Cancer therapies such as chemotherapy, hormonal agents, and anti-angiogenic drugs can exacerbate endothelial dysfunction and increase thrombogenicity. Additionally, certain genetic mutations and patient comorbidities contribute to the overall prothrombotic milieu.

Risk Factors

Risk stratification is essential for guiding prophylactic strategies. Major risk factors include tumor-related variables (type, stage, histology), treatment modalities (chemotherapy, central venous catheters, surgery), and patient-specific factors (age, performance status, comorbidities). Biomarkers such as elevated D-dimer, platelet count, and leukocyte count have been incorporated into risk prediction models. The Khorana Score is widely utilized for ambulatory cancer patients, integrating clinical and laboratory parameters to estimate VTE risk. Other validated tools include the Vienna CATS and COMPASS-CAT scores, which provide nuanced risk assessments in specific patient subsets.

Clinical Features

Cancer-associated VTE often presents with similar clinical features as VTE in non-cancer patients, such as limb swelling, pain, or respiratory symptoms in the case of PE. However, presentations may be atypical or asymptomatic, particularly in patients with advanced disease or those receiving palliative care. Catheter-associated upper extremity thrombosis and visceral vein thromboses are more common in oncology patients. Clinicians should maintain a high index of suspicion, particularly in high-risk populations and those with unexplained clinical deterioration.

Diagnosis

Diagnosis of VTE in cancer patients relies on a combination of clinical suspicion, validated prediction rules, and imaging modalities. Compression ultrasonography remains the gold standard for DVT, while computed tomography pulmonary angiography (CTPA) is preferred for PE. D-dimer testing has limited specificity in cancer patients due to frequent elevation from tumor-related inflammation, but may help rule out VTE in select low-risk cases. Emerging biomarkers and imaging techniques are under investigation to improve diagnostic accuracy and efficiency in this challenging population.

Treatment & Management

Anticoagulation remains the cornerstone of therapy for cancer-associated thrombosis. Low molecular weight heparin (LMWH) has been the preferred agent based on landmark trials demonstrating superior efficacy and safety over vitamin K antagonists (VKAs). Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and edoxaban have increasingly been adopted for selected patients owing to comparable efficacy and convenience, but caution is warranted in those with gastrointestinal malignancies or high bleeding risk. The duration of anticoagulation is individualized, generally extending at least six months, with ongoing therapy considered during active malignancy or persistent risk factors. Multidisciplinary management, patient education, and monitoring for bleeding or recurrence are integral components of care.

Recent Advances / Emerging Therapies

Recent clinical trials have expanded the evidence base for DOACs in cancer-associated VTE, including the Hokusai VTE Cancer, SELECT-D, and CARAVAGGIO studies, which support the use of edoxaban and apixaban in appropriately selected patients. Novel risk assessment algorithms incorporating genetic, proteomic, and machine learning data hold promise for enhancing individualized risk prediction. Research into targeted therapies that modulate the tumor microenvironment or specific coagulation pathways may offer future therapeutic avenues. Ongoing studies are also evaluating optimal strategies for primary prophylaxis in high-risk ambulatory cancer patients, with recent guideline updates reflecting these advances.

Guideline Recommendations

Current guidelines from professional societies such as ASCO, ISTH, and NCCN emphasize risk-adapted approaches to prophylaxis and treatment. Prophylactic anticoagulation is recommended for hospitalized cancer patients and select high-risk ambulatory individuals, guided by validated risk scores. LMWH, and increasingly DOACs, are endorsed for both acute and extended therapy, with agent selection tailored to bleeding risk, drug interactions, and patient preference. Regular reassessment of thrombotic and bleeding risk, as well as patient-centered decision-making, are central to guideline-based care.

Conclusion

Cancer-associated thrombotic events remain a major clinical challenge, necessitating vigilant risk assessment, early diagnosis, and individualized management. Advances in risk prediction, novel anticoagulants, and evidence-based guidelines have improved outcomes, yet ongoing research and multidisciplinary collaboration are essential to further optimize care. Healthcare professionals must remain abreast of evolving evidence and integrate risk-based strategies to reduce the burden of thrombotic complications in oncology practice.